Zeto Unveils NeuroPulse, the First AI-Powered Status Epilepticus Software Using Full 10-20 EEG in Collaboration with encevis

SANTA CLARA, Calif., April 2, 2025 /PRNewswire/ -- Zeto, Inc., a fast-growing medical technology company revolutionizing EEG diagnostics with its cutting-edge devices and advanced cloud platform, announces the integration of live bedside AI-powered Seizure Burden and Status Epilepticus detection. Utilizing encevis, a leading FDA-cleared EEG analysis software developed by the Austrian Institute of Technology, this new capability enhances EEG monitoring with automated detection and notifications for Status Epilepticus—a life-threatening, prolonged seizure condition requiring immediate intervention.

Up to one-third of neurological critical care and emergency department patients are at risk for seizures, which can lead to permanent brain injury and increased mortality risk¹. Access to timely EEG interpretation remains an unmet need, particularly in emergency and critical care settings, where rapid and reliable medical intervention is essential.²

"Our product development has been guided by neurologists, critical and emergency care physicians who sought rapid, clinical-grade EEG with full-head coverage and video to not miss clinically relevant events³. They emphasized the need for accurate bedside seizure detection that enables real-time review and validation by neurologists, ensuring patients receive timely and appropriate treatment," said Aswin Gunasekar, Founder and CEO of Zeto, Inc. "We introduced the Zeto ONE, a best-in-class, full 10-20 EEG system offering rapid setup, video, and remote reading services—being fast embraced by U.S. hospitals. With the addition of AI-powered seizure detection, we now offer a comprehensive, all-in-one solution that significantly enhances neurocritical assessment."

encevis utilizes a cutting-edge AI model to detect seizures, seizure burden, and electrographic status epilepticus. Trained on a diverse dataset of over 21,400 hours of EEG recordings from more than 800 patients, the model was further validated using an independent dataset from 81 patients. Expert reviewers from top U.S. and European institutions meticulously labeled the data, ensuring highly accurate and clinically meaningful insights.

"We are delighted to continue our successful partnership with Zeto," said Dr. Tilmann Kluge, Head of Medical Signal Analysis at AIT Austrian Institute of Technology. "Our algorithms allow physicians to detect seizure burden and electrographic status epilepticus early and with high sensitivity without the need for continuous expert monitoring of the EEG. Our EEG analysis software has been utilized by leading hospitals for over a decade, with capabilities such as artifact reduction, spike and seizure detection with high sensitivity and specificity."

Zeto's full 10-20 EEG platform now features AI-powered seizure burden detection with advanced EEG analysis tools providing comprehensive clinical value for ICU Monitoring as required by ACNS, the American Clinical Neurophysiology Society. Supported by nationwide neurologist reading services, hospitals can expand EEG access without additional infrastructure. More healthcare providers are adopting rapid EEG-powered diagnostics, enabling timely, life-saving decisions.

To learn more about how Zeto's solutions can be integrated into your hospital, contact us at [email protected].

About Zeto, Inc.

Zeto, Inc., an award-winning medical technology company, is at the forefront of advancing EEG brain monitoring and diagnostics in healthcare. Through its innovative wearable devices, Zeto makes brain monitoring accessible in diverse clinical settings, including the ICU, ED, hospitals, offices, and at home. Backed by a powerful cloud-based platform, Zeto delivers nationwide monitoring and interpretation services by neurologists, along with AI-driven notifications for conditions such as seizures and epilepsy. Looking ahead, Zeto plans to expand its capabilities to detect and manage conditions like depression, stroke and traumatic brain injury. Zeto's EEG systems, which received FDA clearances in 2018 and 2024, are currently commercially available in the United States.

To learn more about Zeto's products, please visit: https://zeto-inc.com or email us at [email protected].

About Medical Signal Analysis at AIT (Austrian Institute of Technology)

Medical Signal Analysis at AIT is dedicated to the development of powerful algorithm and medical software solutions for the analysis of neurophysiological data. As part of the Austrian Institute of Technology, Austria's largest non-university research institute, the team of researchers and software professionals developed the CE certified and FDA cleared EEG analysis software suite 'encevis' which is included in EEG platforms in Europe and the US The algorithms and software for Zeto, Inc., are the most recent developments.

¹ Kozak, R., et al. (2023). JACEP Open. 4(4)
² Herman, S.T., et al. (2015) J Clin Neurophysiol. 32(2):87-95
³ Rubin MN, et al. Neurohospitalist (2014) PMID: 24381704; PMCID: PMC3869310

SOURCE Zeto, Inc.